Exhalation Technology Announces Search for Partners for its Covid-19 Rapid Diagnostic Test
Cambridge, England, 24 September 2020 – Exhalation Technology has appointed The Sage Group to lead the partnering program for its novel CoronaCheck™ diagnostic test for Covid-19 in exhaled breath condensate. This is a rapid (<5 minutes) test of high specificity and sensitivity for Covid-19, meeting the need for testing in a wide range of environments.
Exhalation Technology (“ETL”) seeks a global strategic partner with which it can collaborate to exploit its new Covid-19 test. ETL has a strong history in development of diagnostic products based on analysis of the respiratory tract where Covid-19 is prevalent.
ETL has developed a very unique and timely, IP protected test for rapid detection of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2 also known as Covid-19), using a novel biosensor housed in a safe breath analysis device suitable for rapid point-of-care coronavirus testing. The test measures directly the presence of virus in breath, as opposed to antibodies in the blood.
ETL is a UK based company which has developed Inflammacheck®, a device for measuring exhaled breath condensate (EBC) to diagnose and monitor respiratory conditions and diseases. ETL has adapted its Inflammacheck® device, including adding safety features to prevent cross-infection and contamination, to measure the SARS-CoV-2 virus in exhaled breath.
Stig Lytke Brejl, Director of ETL, said “building on an existing CE marked IVD medical device platform is expected to enable a short time to market while at the same time de-risking the project significantly.”
ETL has partnered with a leading biosensor company for the use of their coronavirus biosensor with ETL’s device, CoronaCheck™. The initial product to be launched will measure SARS-CoV-2 in exhaled breath condensate with a reading in under 5 minutes.
Tests on SARS-CoV-2 cultured virus have demonstrated a high degree of sensitivity and specificity of the biosensor. Human pilot tests have commenced, and results are expected in Q4 2020.